Saturday, October 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1glp-1erectile-dysfunctionmens-health

Urologists publish comment on GLP-1 agonists and erectile outcomes

The correspondence in the International Journal of Impotence Research responds to a paper on translating cardiometabolic benefits of incretin drugs into male sexual health.

MH
By Maren Holt · Senior Reporter, GLP-1

The wire

  1. 01Sellke and Eisenberg published a comment in the International Journal of Impotence Research on GLP-1 receptor agonists and male sexual health.
  2. 02Clinicians fielding questions about incretin therapy and erectile function are an audience for this exchange in the urology literature.
  3. 03The item is correspondence rather than new data; the underlying evidence base and any conclusions rest with the original article being discussed.

From the source

Comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes

International journal of impotence research · 2026 Oct 19 · Sellke N, Eisenberg ML et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →